SCHEMBL16610042

SCHEMBL16610042

COc1cc(CO[Si](C)(C)C(C)(C)C)ccc1OC(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.58
MEN1 O00255 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
CYP3A4 P08684 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
SYK P43405 1/20 0.46
VCP P55072 1/20 0.46
HPGD P15428 1/20 0.45
ALPL P05186 1/20 0.43
POLB P06746 1/20 0.43
ALPI P09923 1/20 0.43
ALPG P10696 1/20 0.43
MAPT P10636 4/20 0.43
LMNA P02545 1/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
TP53 P04637 1/20 0.43
DRD2 P14416 1/20 0.42
ALDH1A1 P00352 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610043 0.81 MAPT (0.55) KMT2AMEN1TDP1L3MBTL1MAPT
SCHEMBL16599246 0.81 KMT2A (0.38) KMT2AMEN1TDP1CYP3A4L3MBTL1
SCHEMBL23639738 0.79 KMT2A (0.72) KMT2AMEN1TDP1CYP3A4L3MBTL1
SCHEMBL31321630 0.79 KMT2A (0.72) KMT2AMEN1TDP1CYP3A4L3MBTL1
SCHEMBL16599389 0.79 TSHR (0.50) KMT2AMEN1TDP1L3MBTL1HPGD
SCHEMBL16610045 0.78 KMT2A (0.71) KMT2AMEN1TDP1CYP3A4L3MBTL1
SCHEMBL8128802 0.78 KDM4E (0.44) KMT2AMEN1HPGDMAPTLMNA
SCHEMBL6475832 0.77 KMT2A (0.46) KMT2ATDP1CYP3A4HPGDPOLB
SCHEMBL2950986 0.77 EGFR (0.47) CYP3A4MAPTADRB1ADRB3KDM4E
SCHEMBL9340141 0.77 KMT2A (0.69) KMT2AMEN1TDP1CYP3A4L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3049386-B9 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-11-18 EP disclosed
EP-3049386-B9 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-11-18 EP disclosed
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases UNIVERSITÄT ZU KOLN (DE) 2020-10-06 US disclosed
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases UNIVERSITÄT ZU KOLN (DE) 2020-10-06 US disclosed
EP-3049386-B1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-07-22 EP disclosed
EP-3049386-B1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-07-22 EP disclosed
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2016-08-18 US disclosed
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2016-08-18 US disclosed
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2016-08-18 US disclosed
WO-2015044177-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES APC, BRCA1, VHL KMT2A 3041/4885MEN1 44/4885TDP1 3547/4885
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases APC, BRCA1, VHL KMT2A 3041/4885MEN1 44/4885TDP1 3547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.